Alnylam Pharmaceuticals, Inc.
ALNY
Revenue
1.10B
▼-151.99M▼-12.17%
3 Months ChangeAssets
4.97B
▲114.67M▲2.36%
3 Months ChangeLiabilities
4.18B
▼-440.61M▼-9.54%
3 Months ChangeFree Cash Flow
-127.28M
▼-32.80M▼-34.71%
12 Months ChangeRevenue/Cost Of Revenue
Loading...
Net Profit/Loss
Loading...
Assets/Liabilities
Loading...
Cash Flows
Loading...
Loading...
Loading...
Recent Quarterly and Annual Filings
2026-03-04
Form 8-K
ID: 0001628280-26-014728
2026-02-12
Form 8-K
ID: 0001628280-26-007491
2026-01-12
Form 8-K
ID: 0001628280-26-001755
2025-12-11
Form 8-K
ID: 0001193125-25-315047
2025-12-03
Form 8-K
ID: 0001628280-25-055084
2025-10-30
Form 10-Q
ID: 0001628280-25-047345
2025-10-30
Form 8-K
ID: 0001628280-25-047342
2025-10-03
Form 8-K
ID: 0001193125-25-230201
2025-09-12
Form 8-K
ID: 0001193125-25-202366
2025-09-10
Form 8-K
ID: 0001193125-25-199686